An investigational new drug (IND) application is a requirement for drug developers looking to conduct any trials in the U.S. The IND, overseen by the FDA in the U.S., is particularly notable for its thorough and product-specific approach. A pre-IND (PIND) and IND application process thus serves as an optimal vehicle for business planning and communicating with various external stakeholders who ultimately dictate investment decisions and market access.
Read this white paper to learn more about:
- The benefits of opening an IND beyond the initial enabling regulatory requirements
- Strategic business opportunities presented through collaboration and networking
- Using the IND process to frame clinical development and global marketing considerations
